Skip to content Skip to sidebar Skip to footer

Newsletter

Nick Sundich

1,254 articles published

Healthcare Stocks Life Sciences

Imugene (ASX:IMU): This exciting biotech has multiple clinical trial readouts expected in the next 12 months

Imugene (ASX:IMU) is still valued at over $400m, in spite of being valued at over $2bn back in 2021 and having had a rollercoaster 12 months. Imugene (ASX:IMU) share price chart, log scale (Source: TradingView) Even though it has assets that have passed Phase 2 trials, it has never gotten to Phase 3. Yet it has $93.1m…

ByNick SundichOctober 22, 20240Comments

Energy Stocks

Do oil and gas stocks have a future? Not if the IEA forecasts for 2050 oil demand are correct

Do oil and gas stocks have a future...at all? And if they do, what does it look like? Evidently, it won't be anything like the previous century as the world turns to renewable energy. It is not quite dead yet - after all, the world consumed 100 million barrels per day (mb/d) according to the…

ByNick SundichOctober 21, 20240Comments

Industrials

Betting stocks: How do they make their money? Here are the top 4 ways

The revenue model of Betting stocks is different to any other industry and can confuse even the most seasoned analysts. In this article, we recap just how they work so that investors can better understand their business models. What are the Best ASX Stocks to invest in right now? Check our buy/sell tips[sg_popup id="23914" event="click"][/sg_popup] How do…

ByNick SundichOctober 18, 20240Comments

Mining Stocks Rare Earths Stocks Small Caps Stocks Uncategorized

Osmond Resources (ASX:OSM): The stars are lining up for this company with its Orion EU Critical Minerals Project

On 6 September 2024 the stock of the mineral explorer Osmond Resources (ASX: OSM) started coming back to life. Before then it was bumping along at around 7 cents per share. Suddenly investor interest in took off, after the company announced it was buying into the Orion EU Critical Minerals Project in Spain. Osmond stock…

ByNick SundichOctober 16, 20240Comments

Uncategorized

AMP (ASX:AMP): It is up 50% since November 2023! Is a better future ahead?

One time wealth management giant AMP (ASX: AMP) has endured a massive fall from grace over the years. There is an argument to be made that now is turnaround time, since it now has a banking brand and wealth management platform, which are both performing well. And shares are up over 50% since November last…

ByNick SundichOctober 16, 20240Comments

Agriculture Stocks Bank Stocks

Here are 5 companies that use an October to September financial year, and are reporting FY24 results soon

If you thought reporting season was done and dusted for all companies, you'd be wrong - because some companies use an October to September financial year. And these companies will be reporting in the next few weeks. Most use a July to June financial year, but can use whatever 12 month period they like as…

ByNick SundichOctober 16, 20240Comments

Healthcare Stocks

Island Pharmaceuticals (ASX:ILA): One of the rare ASX biotechs fighting mosquito diseases – and it’s in Phase 2

Island Pharmaceuticals (ASX:ILA) is one of the few (if not the only) ASX-listed Biotechs that is focused on mosquito diseases, primarily Dengue fever. Mosquito diseases, such as Dengue, are expensive to treat and are expected to proliferate due to climate change and the consequential boom in the mosquito population. But maybe Island Pharmaceuticals can help. Introduction…

ByNick SundichOctober 15, 20240Comments

Healthcare Stocks Life Sciences

Here’s why you’ll see more ASX biotechs focus on Asia in the years ahead!

Investors should expect to see more ASX biotechs focus on Asia in the years ahead. And there are good reasons why.For many companies, the golden market has been the USA, given its population and stringent regulator the Food and Drug Administration (FDA). If a company can commercialise a drug in the USA, it can succeed…

ByNick SundichOctober 15, 20240Comments

Education

Here are 5 useful ways other than NPAT to measure a company’s performance

How can you judge measure a company’s performance other than through NPAT? NPAT (Net Profit After Tax) is a useful guide but it should not be the sole measure of judging a company's performance. After all, it does not take into account other significant factors, such as investments made in the business, changes in market conditions,…

ByNick SundichOctober 14, 20240Comments

Education

So your company announced a non-binding MOU: Is it a genuine deal or desperate puffery?

When you're invested in a microcap stock, you might hear it has signed a 'non-binding MOU' (short for Memorandum of Understanding). It is said that the journey of a thousand miles begins with the first step. Are they the first step of a long journey, or just desperate puffery? What is a 'non-binding MOU'? A Memorandum…

ByNick SundichOctober 11, 20240Comments

the Kick-ass Multipurpose WordPress Theme

Nick Sundich

Imugene (ASX:IMU): This exciting biotech has multiple clinical trial readouts expected in the next 12 months

Do oil and gas stocks have a future? Not if the IEA forecasts for 2050 oil demand are correct

Betting stocks: How do they make their money? Here are the top 4 ways

Osmond Resources (ASX:OSM): The stars are lining up for this company with its Orion EU Critical Minerals Project

AMP (ASX:AMP): It is up 50% since November 2023! Is a better future ahead?

Here are 5 companies that use an October to September financial year, and are reporting FY24 results soon

Island Pharmaceuticals (ASX:ILA): One of the rare ASX biotechs fighting mosquito diseases – and it’s in Phase 2

Here’s why you’ll see more ASX biotechs focus on Asia in the years ahead!

Here are 5 useful ways other than NPAT to measure a company’s performance

So your company announced a non-binding MOU: Is it a genuine deal or desperate puffery?

Stocks in Spotlight

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Nick Sundich

Stocks in Spotlight

Add Your Heading Text Here